Ambrx Biopharma Inc. to Present at the H.C. Wainwright Preclinical Cancer Drug Discover Conference
June 28 2022 - 4:05PM
Business Wire
Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage
biopharmaceutical company using an expanded genetic code technology
platform to create Engineered Precision Biologics (EPBs), today
announced that Feng Tian, Ph.D., Chairman of the Board, President
and CEO of Ambrx, will participate in the virtual H.C. Wainwright
Preclinical Cancer Drug Discover: Emerging Targets and Modalities
Conference on Wednesday, June 29, 2022.
Dr. Tian will participate in a virtual presentation that will be
available on demand starting on Wednesday, June 29, 2022 at 7:00 AM
Pacific Time / 10:00 AM Eastern Time.
Dr. Tian will participate in a live panel discussion moderated
by Robert Burns on the treatment landscape of HER2 on Wednesday,
June 29, 2022 at 9:00 AM Pacific Time / 12:00 PM Eastern Time.
Interested parties can access the live and pre-recorded webcasts
for these conferences from the Investor Relations section of the
company's website at www.Ambrx.com. The webcast replays will be
available after the conclusion of the respective presentations for
approximately 90 days.
About Ambrx Biopharma Inc. (Ambrx)
Ambrx is a clinical stage biopharmaceutical company using an
expanded genetic code technology platform to discover and develop
Engineered Precision Biologics. These include next generation
antibody drug conjugates (ADCs), bispecifics, targeted
immuno-oncology therapies, novel cytokines to modulate the immune
system, and long-acting therapeutic peptides for metabolic and
cardiovascular disease. Ambrx is advancing a robust portfolio of
clinical and preclinical programs designed to optimize efficacy,
safety and ease of use, in multiple therapeutic areas, including
its lead product candidate ARX788. In addition, Ambrx has clinical
collaborations with multiple partners, for drug candidates
generated using Ambrx technology. For more information, please
visit www.ambrx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220628006027/en/
INVESTORS Laurence Watts Managing Director Gilmartin Group, LLC.
619-916-7620 ir@ambrx.com
MEDIA media@ambrx.com
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ambrx Biopharma (NYSE:AMAM)
Historical Stock Chart
From Apr 2023 to Apr 2024